- Home
- MVST vs MYGN Comparison
MVST vs MYGN Comparison
Compare MVST & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- MYGN
- Stock Information
- Founded
- MVST 2006
- MYGN 1991
- Country
- MVST United States
- MYGN United States
- Employees
- MVST N/A
- MYGN N/A
- Industry
- MVST Industrial Machinery/Components
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MVST Miscellaneous
- MYGN Health Care
- Exchange
- MVST Nasdaq
- MYGN Nasdaq
- Market Cap
- MVST 676.9M
- MYGN 744.7M
- IPO Year
- MVST N/A
- MYGN 1995
- Fundamental
- Price
- MVST $2.20
- MYGN $3.89
- Analyst Decision
- MVST Strong Buy
- MYGN Hold
- Analyst Count
- MVST 1
- MYGN 16
- Target Price
- MVST $3.00
- MYGN $16.63
- AVG Volume (30 Days)
- MVST 5.6M
- MYGN 2.9M
- Earning Date
- MVST 05-12-2025
- MYGN 05-06-2025
- Dividend Yield
- MVST N/A
- MYGN N/A
- EPS Growth
- MVST N/A
- MYGN N/A
- EPS
- MVST N/A
- MYGN N/A
- Revenue
- MVST $379,801,000.00
- MYGN $831,300,000.00
- Revenue This Year
- MVST $24.34
- MYGN $2.96
- Revenue Next Year
- MVST $29.60
- MYGN $8.36
- P/E Ratio
- MVST N/A
- MYGN N/A
- Revenue Growth
- MVST 23.87
- MYGN 7.38
- 52 Week Low
- MVST $0.15
- MYGN $3.98
- 52 Week High
- MVST $2.87
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- MVST 61.86
- MYGN 17.24
- Support Level
- MVST $1.82
- MYGN $6.94
- Resistance Level
- MVST $2.08
- MYGN $7.81
- Average True Range (ATR)
- MVST 0.15
- MYGN 0.50
- MACD
- MVST -0.00
- MYGN -0.29
- Stochastic Oscillator
- MVST 65.52
- MYGN 0.74
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.